Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Azithromycin: critical points]

A Philippon1, R Cluzel, C J Soussy

  • 1Université Paris VII, Hôpital Saint-Louis, Service de Bactériologie-Virologie-Hygiène, Paris, France.

Pathologie-Biologie
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study.

Diagnostic microbiology and infectious disease·2015
Same author

[Not Available].

Annales de genetique et de selection animale·2012
Same author

[Enterobacteriaceae and beta-lactams : wild susceptibility patterns].

Pathologie-biologie·2012
Same author

[Lactobacillus delbrueckii: probable agent of urinary tract infections in very old women].

Pathologie-biologie·2010
Same author

[Activity of doripenem against anaerobic bacteria].

Pathologie-biologie·2010
Same author

Comparative in-vitro activity of cefsulodin and ceftazidime against ticarcillin-resistant Pseudomonas aeruginosa.

The Journal of antimicrobial chemotherapy·2009
Same journal

Pathologie-biologie·2020
Same journal

Antibacterial and antibiofilm activities of Laurus nobilis L. essential oil against Staphylococcus aureus strains associated with oral infections.

Pathologie-biologie·2015
Same journal

[Not Available].

Pathologie-biologie·2015
Same journal

Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol.

Pathologie-biologie·2015
Same journal

Biological diagnosis of diabetes mellitus.

Pathologie-biologie·2015
Same journal

Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis.

Pathologie-biologie·2015
See all related articles

French breakpoints for azithromycin were established using clinical, pharmacokinetic, and bacteriological data. Azithromycin shows variable activity against Gram-positive bacteria but is more effective against key Gram-negative pathogens.

Area of Science:

  • Microbiology
  • Pharmacology
  • Clinical Science

Background:

  • Azithromycin is an acid-stable, orally administered antimicrobial agent.
  • Establishing clinical breakpoints is crucial for guiding antimicrobial therapy.
  • Previous studies have indicated varying in vitro activity profiles for azithromycin.

Purpose of the Study:

  • To determine the French clinical breakpoints for azithromycin.
  • To evaluate the bacteriological, pharmacokinetic, and clinical criteria for breakpoint determination.
  • To assess azithromycin's in vitro activity against various bacterial pathogens.

Main Methods:

  • Bacteriological testing of azithromycin against Gram-positive and Gram-negative organisms.
  • Pharmacokinetic and clinical data analysis.

Related Experiment Videos

  • Determination of preliminary azithromycin breakpoints based on established criteria.

    • Main Results:

    • Azithromycin demonstrated lower in vitro activity than erythromycin against Gram-positive bacteria but higher activity against key Gram-negative pathogens like Neisseria gonorrhoeae and Haemophilus influenzae.
    • Azithromycin's activity was unaffected by inoculum size, pH, or serum, but not by CO2 for anaerobes.
    • Preliminary breakpoints for azithromycin were set at <= 0.12 mg/l and > 4 mg/l.

    Conclusions:

    • French breakpoints for azithromycin were established using a combination of criteria.
    • Azithromycin exhibits a distinct activity spectrum compared to erythromycin, particularly against Gram-negative bacteria.
    • Further research is needed to confirm azithromycin's efficacy against additional bacterial species.